Technology Listings


GIFT4: GM-CSF and IL-4 Fusion Protein for Treating Cancer and Infectious Diseases

Application

A recombinant fusion cytokine that activates host immune responses for the treatment of cancer or infectious diseases and the development of adjuvant vaccines.

Key Benefits
  • Retains the immune stimulatory properties of both its parental molecules.
  • Displays novel functions such as direct activation of B cells leading to anti-cancer and vaccine adjuvant activity.
Technical Summary

Cytokines are small cell-signaling proteins with immuno-modulatory properties. GM-CSF and IL-4 are two important cytokines with immuno-stimulatory activities, GM-CSF affects adaptive immunity by promoting antigen presentation and co stimulation by dendritic cells and IL-4 has important roles in antibody class switching and lymphocyte activation and proliferation. Both of these proteins have been used in the past alone or in combination to boost host immune responses against cancer or infectious diseases. Alone, these immune responses have been clinically insufficient. Drs. Galipeau and Deng at Emory University have bio-engineered a novel fusion cytokine combining GM-CSF and IL-4, named GIFT4, which in addition to performing the individual biological functions of its parental molecules, displays unique gain of function immuno-stimulatory effects. GIFT4 directly activates adaptive B cells and induces the expansion of effector B cells and antigen specific antibody-secreting plasma cells both in vitro and in vivo. Clinical applications for GIFT4 include the ex vivo expansion of B cells for cellular therapies (both oncology and others), use as abiologic therapy for oncology applications, or use as an adjuvant therapy for the treatment of infectious diseases.

Developmental Stage

Anti-tumor and vaccine activity of GIFT4 has been tested in animal model against B16F0 melanoma with positive results.

View our feature innovation

 

Patent Information
App Type Country Serial No. Patent No. File Date Issued Date Expire Date Patent Status
Nationalized PCT - United States United States 14/436,491 9,657,076 4/17/2015 5/23/2017 10/23/2033 Issued
Nationalized PCT - Foreign Japan 2015-538149 6430949 4/20/2015 11/28/2018 10/23/2033 Pending
Nationalized PCT - Foreign EP 13849808.4 2912069 5/20/2015 7/31/2019 10/23/2033 Issued
EP Registered Country Germany 13849808.4 2912069 5/20/2015 7/31/2019 10/23/2033 Issued
EP Registered Country France 13849808.4 2912069 5/20/2015 7/31/2019 10/23/2033 Issued
EP Registered Country Ireland 13849808.4 2912069 5/20/2015 7/31/2019 10/23/2033 Issued
EP Registered Country United Kingdom 13849808.4 2912069 5/20/2015 7/31/2019 10/23/2033 Issued
Nationalized PCT - Foreign China 2013800660946 ZL 2013 8 00660946 6/17/2015 10/9/2018 10/22/2033 Pending
Divisional United States 15/491,777 10,093,709 4/19/2017 10/9/2018 10/23/2033 Issued
Divisional China 2018110514137   9/10/2018     Pending
Continuation United States 16/149,372 10/2/2018     Pending
Divisional EP 19185874.5   7/11/2019     Pending
Tech ID: 12066
Published: 1/8/2013
Category
Therapeutics
Vaccines

Contact
Sarah Wilkening
Licensing Associate
Emory University
(404) 727-1969
sarah.wilkening@emory.edu

Inventor(s)
Jacques Galipeau
Jiusheng Deng

Keywords
Biologic
Microbiology/Infectious Diseases
Oncology